Table of Contents
Haleon has sold its Nicotinell, Habitrol and Thrive brands to the Indian pharmaceutical company Dr Reddy’s Laboratories
Healthcare giant Haleon is divesting the nicotine substitute brands it sells outside the US for £500m.
Indian pharmaceutical company Dr Reddy’s Laboratories is acquiring products such as Nicotinell, Habitrol and Thrive, which are sold in 30 markets around the world in the form of pills, patches and gum for people who want to quit smoking.
Haleon, the maker of Sensodyne and Panadol, which is listed in London and New York, said it agreed to the sale as part of ongoing efforts to trim its portfolio of consumer health products.
Earlier this year it sold its ChapStick lip balm brand, while last year it ditched athlete’s foot treatment Lamisil.
Haleon, which was spun off from pharmaceutical giant GSK in 2022, said its non-US nicotine replacement therapy business generated net income of £217 million in 2023.
DIY INVESTMENT PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-to-use portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free Fund Trading and Investment Ideas
interactive investor
interactive inverter
Fixed fee investing from £4.99 per month
eToro
eToro
Stock Investment: Community of over 30 million
Trade 212
Trade 212
Free stock trading with no commissions per account
Affiliate links: If you purchase a This is Money product you may earn a commission. These offers are chosen by our editorial team as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investment account for you
